ED (N = 655)
| Â | Â | Â | Â | Â | Â | Â | Â |
---|
 | Age of Onset | LVMass Adj* | LVEF Adj** | Survival |
---|
 | SNP Main Effects | SNP-SNP Interaction | SNP Main Effects | SNP_SNP Interaction | SNP Main Effects | SNP_SNP Interaction | SNP Main Effects | SNP_SNP Interaction |
---|
Number of tests | 22 | 209 | 22 | 200 | 22 | 204 | 22 | 231 |
P < 0.10 | 2 | 24 | 1 | 8 | 2 | 16 | 4 | 50 |
FDR (<0.30) | 0 | 0 | 0 | 0 | 2 | 0 | 4 | 44 |
Cross Validation*** | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 10 |
FDR and Cross-validation | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 6 |
- * LVMass was adjusted for age of onset, sex, height, weight, hypertension
- ** LVEF was adjusted for age of onset, sex
- *** For survival analysis, Risk Index was used to cross-validate, P-value for Cox model with Risk Index <0.1 is considered as crossvalidated. For continuous outcomes, 4-fold CV was used. Press-Rsquared >0.005 (SNP univ model) or Press-Rsquared for full model >0 and Press-Rsquared Difference between full model and submodel >0.005 (Epistasis) is considered to be crossvalidated for interaction.